Short answer
Vir Biotechnology, Inc. (VIR) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$126M
- −3.9% YoY
- EPS (diluted)
- −$0.85
- +3.4% YoY
Source: XBRL data from the Vir Biotechnology, Inc. (VIR) Q1 2026 10-Q on SEC EDGAR. USD.
Vir Biotechnology, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $(29) thousand, down $3.061 million YoY from $3.032 million
- Net loss $125.695 million vs $120.965 million YoY
- Best-performing line: license and collaboration revenue $(41) thousand vs $(70) thousand
- Cash, equivalents and investments $809.3 million at March 31, 2026
- Operating cash outflow $132.386 million vs $78.116 million; financing provided $162.523 million
- Near-term catalysts: ECLIPSE 1 data expected Q4 2026; ECLIPSE 2 and 3 data expected Q1 2027
Risk Factors
- Net loss $125.7 million versus $121.0 million year over year, with accumulated deficit reaching $1.3 billion
- Astellas collaboration became effective April 15, 2026, triggering a $240 million upfront payment and $75 million stock sale
- FDA, EMA and European orphan designations for tobevibart-elebsiran may not accelerate approval or be maintained
- Oncology trials combine product candidates with pembrolizumab, enzalutamide and darolutamide, increasing attribution and combination-toxicity risks
- Cash, cash equivalents and investments of $809.3 million expected to fund operations at least 12 months, subject to changing clinical needs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Vir Biotechnology, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.